Sign in

CAMX on Nasdaq Stockholm AB

Camurus

Logo: Camurus, Public domain, via Wikimedia Commons4

Swedish pharmaceutical company

Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures.2 Its shares trade on Nasdaq Stockholm AB under the symbol CAMX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1991Founded1

Compare with another stock.

  • TickerCAMX on Nasdaq Stockholm AB1
  • Industrypharmaceutical industry1
  • HeadquartersLund1
  • Websitewww.camurus.com
  • Legal formAktiebolag3
  • LEI5493003S6Z6VI7WYFQ063
  • StatusActive3
  • LEI statusIssued and current3
  • Registered addressRydbergs torg 4, 224 84 Lund, Sweden3
  • Registered withSwedish Companies Registration Office, 556667-91053

See how the biggest companies compare on our leaderboards

Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.2

Corporate structure

Camurus sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Camurus Lund, Sweden
    • Camurus Development AB Subsidiary · Lund, Sweden

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0). Each entity in the chart links to its source.

Leadership

Who has led Camurus, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Products and brands

Technologies

Camurus is a company focused on the development of lipid lyotropic liquid crystal structures for pharmaceutical drug delivery applications. These structures are well-defined three-dimensional formations consisting of lipophilic and hydrophilic domains that can be either interconnected or isolated depending on the environmentally induced phase conditions. The unique crystalline structures offer a unique way of encapsulating and transporting Active pharmaceutical ingredients, such as small molecules, peptides and proteins through the body. The structures also allow for the use of controlled release and prevention of degradation of fragile short half live molecules, a serious issue for amino-acid based drugs.

FluidCrystal technology

Camurus' FluidCrystal are available as injectable depots and topical bioadhesive delivery technologies. By encapsulating the drug compound in the nanostructures, injectable depots are able to deliver therapeutic levels of drug substance over extended periods from a single injection. This leads to a decrease in traditional side effects associated with high initial drug release on injection (drug burst), poor drug stability, and complex processing requirements, making the system highly suitable for sustained parental delivery of peptides, proteins, and small molecule drug compounds. The topical delivery system creates a bio-adhesive film that provides local and continual release of drug compounds. The delivery system is suited for delivery of peptide, protein, and small molecule drug compounds and can be applied to dermal, buccal, ophthalmic, nasal, vaginal, and other topical surfaces.

Products

Elyzol dental gel - parodontitis

Camurus has partnered with Colgate-Palmolive for the marketing of their Elyzol dental gel for the treatment of parodontitis. Elyzol 25% dental gel contains metronidazole in the form of metronidazole benzoate as the active substance.

Episil - oral mucositis pain

Oral mucositis is a severe side-effect of chemotherapy or radiotherapy during cancer treatment, and is often a dose-limiting factor in treatment. episil is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity.

Read the full text

It has been demonstrated in several clinical trials that episil gives an immediate and significant reduction of pain. This analgesic effect was maintained over at least 8 hours following administration. The treatment was reported to be safe and well tolerated. The product is registered as a medical device in a wide range of countries, including the European Union and the United States.

CAM2029 - growth hormone disorders

CAM2029 is a product for the treatment of acromegaly and carcinoid tumours. CAM2029 was assessed in a double blind, randomized, parallel-group, placebo controlled Phase I trial. CAM2029 is partnered with Novartis.

CAM2032 - prostate cancer

CAM2032 is a new drug being developed for long-term treatment of prostate cancer, with development also initiated for endometriosis. Camurus has completed a Phase IIa clinical trial of CAM2032 in patients with advanced metastatic prostate cancer.

CAM2038 - drug addiction

CAM2038 represents a new treatment concept for opiate addiction based on the well-documented anti-addiction therapeutic buprenorphine. CAM2038 is developed as a sustained release injection depot.

From Wikipedia’s article on Camurus, shared under CC BY-SA 4.0.5

Timeline

  1. 1991Founded Founded1

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cambiar Investors LLC397,673$13.6M0.6%No change
Cdkv Holdings LLC18,328$626.3K0.5%−826
Kohmann Bosshard Financial Services, LLC11,482$392.4K0.0%No change
Waddell & Associates, LLC10,604$362.4K0.0%No change
Advisory Advocates, LLC8,170$279.2K0.2%No change
Jane Street Group, LLC7,003$239.3K0.0%New
UBS Group AG355$12.1K0.0%+161
Morgan Stanley118$4.0K0.0%No change
Key Financial Inc44$1.5K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5